Zlata Mujagić1*, Nahida Srabović1, Hamza Mujagić2.The role of prolactin in human breast cancer. Biochemia Medica 2009;19(3):236-49. http://dx.doi.org/10.11613/BM.2009.022
1Department of Biochemistry, Faculty of Pharmacy, University of Tuzla, Bosnia and Herzegovina
2Massachusetts General Hospital and Harvard University, Boston, USA
Corresponding author*: zlata [dot] mujagic [at] gmail [dot] com
Much of the literature on human breast cancer and prolactin (PRL) appears to be contradictory. PRL has been first recognizedas a hormone that plays an important role in breast cancer initiation and development in rodents, and, at least partly, in humans. Bioactive PRL is synthesized by human breast cancer cells in culture and acts in an autocrine/paracrine stimulatory loop within breast tissue. The actions of this ligand are mediated by PRL receptor (PRLR) isoforms found on, or secreted by, humanbreast epithelium. The PRL/PRLR complex associates with,and activates, several signaling pathways that are shared withother members of the cytokine receptor superfamily. Proximal PRLR signaling is initiated by three tyrosine kinases, namely Jak2, Src, and Tec. Some recent literature data have indicated a functional role forPRL within the nucleus where it acts in a complex with cyclophilin B as a transcriptional inducer. Several epidemiological studies have indicated that PRL mayalso function as a progression factor for human breast cancer. PRL might be an important local growth promoter involved in the pathogenesis of human breast cancer. Hyperprolactinemia could be an indicator of disease progression and poor prognosis and clinical approaches to controlling this disease need to incorporate antagonists of PRL/PRLR interaction or PRL receptor-associated signaltransduction.
Key words: prolactin; breast cancer; prolactin receptors; prolactin signaling pathways; hyperprolactinemia
Accumulated data about the role of prolactin (PRL) in human breast cancer appear to be controversial. Thus, it has been difficult to establish definitive involvement of PRL in human breast disease. PRL was first recognizedas a hormone that plays an important role in breast cancer initiation and development in rodents (1,2) and, at least partly, in humans. There is also firm evidence of a direct stimulatory role of PRL on mammary epithelial cells (3,4), and breast cancer cells in culture (5,6). There are also some epidemiological studies showing significant increase in serum PRL concentrations in certain subpopulations of breast cancer patients (7-10), and in women at risk of developing familial breast cancer (9,11). This paper examines the basis for a claim that PRL has a contributory role during breast oncogenesis.
Actions of PRL within mammary tissues – in vitro investigations
Synthesis and secretion of PRL by breast cancer cells
Both endocrine and autocrine/paracrinesources of PRL have been recognized to exist in mammals. For many years, evidence in the literature has hinted at the possibility of an extrapituitary source of PRL. Evidence from the 1970’s indicatedthat hypophysectomized breast cancer patients had near-normalPRL levels (12,13), whereas immunohistochemistry studies revealedthe expression of immunoreactive PRL protein in human breastepithelium (14). In addition, low levels of circulating PRL were found to persist in patients under pituitary hormone suppression therapy (15). Studies in the early 1990’s indicated that the mRNA for PRL couldbe found in normal and neoplastic human breast epithelium (16-18), and mammary epithelium from pregnant rodents (19,20). PRL is generated by tumors as well as by a variety of normal tissues. Placenta is the richest source of the extrapituitary PRL (21), and is responsible for its high level in human amniotic fluid. Immune system, uterus, brain and dermal fibroblasts also produce PRL (21-24). These findings led both Vonderhaar and Clevenger laboratories (17,18) to hypothesize and subsequently prove that PRLis synthesized and secreted in human breast tissues and cells. Bioactive PRL is synthesized by human breast cancer cells in culture and acts in an autocrine/paracrine stimulatory loop within breast tissue, suggesting a role for this hormone in the pathogenesis of breast cancer (17,18). The growth of both T47Dco (ER-negative) and MCF-7 (ER-positive) human breast cancer cells was inhibited after treatment with monoclonal antibodies raised against human pituitary PRL (17). In addition, antisense RNA directed against the gene encoding for pituitary PRL significantly inhibited growth of T47Dco cells (25). The presence of the mRNA for PRL in T47Dco and MCF-7 was confirmed by RT-PCR (reverse transcription polymerase chain reaction) (17), and 82% of all tested breast cancer cell lines contained mRNA for PRL (25). Furthermore, the vast majority,i.e. 98% of human breast cancers synthesize PRL mRNA as detectedby in situ hybridization (26). In addition, some studies revealed that more than 75% of primary breast cancer surgical samples also contain mRNA for PRL, and, in the majority of cases, the amount of mRNA for PRL and its receptors is significantly elevated in malignant vs. the adjacent, non-malignant tissue from the same patient (16,25,27).
PRL receptors (PRLR)
The actions of PRL in the mammary gland require the presenceof its cognate cell surface receptor, the PRLR. PRLR belongs to the cytokine hematopoietic family of receptors (28,29). The members of this superfamily are single membrane-spanning receptors with three domains: an extracellular ligand binding domain, a hydrophobic transmembrane domain, and an intracellular proline-rich domain. There are at least three different isoforms of PRLR differing mainly in their cytoplasmic domain: long (90 kDa), intermediate, and short (40kDa) isoform. Long and short isoforms of PRLR are generated by differential splicing of a single gene and differ only in the length of the cytoplasmic domain (30). The intermediate form is a deletion mutant of the long form, lacking 198 aminoacids in its cytoplasmic domain. The shortest PRLR isoform, the PRL binding protein (PRLBP) was identified in human serum (31) and it represents the freely circulating extracellular domain of the PRLR (32). All three isoforms promote mitosis (33). Both normal and malignant mammary cells contain both the long and short forms of PRLR (34,35), while the intermediate form is found in Nb2 lymphoma cells and is more sensitive to PRL compared with the other two forms of PRLR (36). The intermediate form of PRLR has been detected in breast tissue samples (37), in contrast to the results from another study (18). Advances in immunohistochemistry, insitu hybridization, and RT-PCR enabled increasingly sensitive estimationof the PRLR in human breast cancer, and results of some of the studies using thesetechnologies (26,35,37,38) have revealed that the hPRLR is expressed in upto 98% of all human breast cancers. The studies examining PRLRexpression at the mRNA level have suggested an association witheither ER/PR (estrogen/progesterone receptors) expression (38) or neoplasia (37); however, studiesat the protein level have not confirmed these observations (26).The PRLR are commonly stabilized in human breast cancer due to decreased phosphorylation of residue Ser349 which, when phosphorylated, recruits the beta Trcp E3 ubiquitin ligase and facilitates PRLR degradation (39).
Neoplastic development and progression require deregulated cell proliferation,increased cellular survival, acquisition of an adequate vascularsupply, and escape from constraints on motility. Despite evidence that PRL can trigger the growth and motility of human breast cancer cells, the inability of PRL to trigger differentiation remains uncertain. Potential mechanisms include alterations in Stat5 (signal transducer and activator of transcription) levels or phosphorylation, quantitative changes in the expression of various hPRLR isoforms, or alteration in the malignant epithelial cell’s responsiveness to the basement membrane, which could indirectly impact PRLR signaling (32). Because enhanced motility is one aspect ofthe metastatic process, it has been questionedwhether PRL could serve as a chemoattractant for human breastcancer in vitro (40). PRL stimulates the cytoskeletal r-organization and motility of breast cancer cells. During PRLR signaling, Vav2 (guanine nucleotide exchange factor) becomes phosphorylated and activated, an event regulated by the serine/threonine kinase Nek3 (never in mitosis gene a-related kinase 3) which contributes to PRL-mediated breast cancer motility through mechanisms involving Rac1 (guanine nucleotide exchange factor) activation and paxillin phosphorylation (41).
PRL may also influence mammary carcinogenesis bymodulating vascularization. It was shown that hPRL itself, as wellas human GH, and placental hormones, could also stimulate formation of capillaries inthe chicken chorioallantoic membrane assay (42). In contrast,a proteolytic cleavage product of PRL, 16K-PRL, is a potentantiangiogenic agent in vivo and in vitro (42-44). ThisN-terminal cleavage product of PRL inhibited endothelial cellproliferation in response to vascular endothelial growth factor (VEGF)and basic fibroblast growth factor (BFGF) by inhibiting the Ras-Raf1-MAPK signaling pathway and increasing expression of type 1 plasminogen activatorinhibitor (42,45,46). These activities appear to be mediatedby a receptor distinct from the PRLR (47). The induction of VEGF by PRL is PRLR-, Jak2-, and MAP kinase-dependent. PRL induces VEGF expression through Erg-1 (ether-a-go-go-related gene 1 encoded K+ channels), and implicates VEGF as an intermediary of PRL-regulated angiogenesis (48).
The role of PRL in breast cancer is complicated by the fact that PRL itself is angiogenic, but proteases cleave PRL to generate vasoinhibins, a family of peptides that act on endothelial cells to suppress angiogenesis and vasodilation and to promote apoptosis-mediated vascular regression (49).
PRL/PRLR signaling pathways
Upon PRL-induced receptor dimerization, several different kinases are activated to transduce the hormonal signal. Proximal PRLR signaling is initiated by three tyrosine kinases, namely Jak2 (Janus kinase), Src (sarcoma), and Tec (protein tyrosine kinase) (32). These kinases belong to the Janus family of kinases (Jak family). Multiple additional downstream pathways, suchas Src family kinases, Ras-MAPKs (rat sacoma-mitogen-activated protein kinases), and PI3K (phosphoinositide 3 kinase) are involved in PRL signaling (50) (Figure 1).
Figure 1. Aspects of PRLR signaling pathways. PRL-induced receptor dimerization induces the association of the Jak2 kinase, resulting in the activation of Jak2, PRLR phosphorylation, and the association and phosphorylation of Stat5. Signaling through the SHC/GRB2/Ras/Raf/MEK/MAPK pathway also directly stimulates proliferation and modulates Stat activity. The complex between the Tec tyrosine kinase and the Vav family of guanine nucleotide exchange factors also inducibly associates with ligand-bound PRLR resulting in its activation and stimulation of cellular motility (modified according to ref. 32).
Although it is not clear that all PRL signaling requires Jak2 as a proximal intermediate(50,51), a great deal of evidence in many cell typessupports a key role for this kinase in many actions of PRL (52,53). Jak2 phosphorylates multiple substrates, including thePRLR and Jak2 themselves. This provides docking sites for proteinswith SH2 (src homology2) domains, including Stats. The binding of PRL to its receptors induces tyrosine phosphorylation of cytoplasmic transcription factors, mainly Stat family members (32,54). Activation of Stat proteins results in their translocation to the nucleus, and subsequent activation of gene transcription (32,55). Stat1, Stat3 and Stat5 are activated in T47D cells within 15 min of PRL treatment (56). Several studies have demonstrated increased levels of Stats1 and 3 in primary mammary tumors(57,58). However, theirtarget genes in oncogenic processes, the relative importanceof PRL in their regulation, and differences from the normalmammary gland have not been understood. Both Stats3 and 5 are involvedin PRL activation of the cyclin D1 promoter (59), suggestingat least one target of PRL through this pathway that could contributeto tumorigenesis. It has beendemonstrated (60) that Stat5b, rather than Stat5a, is a potentmediator of Src-induced tumorigenesis. As discussed above, tyrosine phosphorylationby a receptor-associated Jak2 kinase resultsin the dimerization/multimerization and nuclear retrotranslocationof the Stat complex where it engages its cognate DNA bindingsequence, resulting in promoter transactivation under appropriateconditions (32,61). Whereas PRL stimulated tyrosinephosphorylation and nuclear translocation of both Stats5a and5b, Src activation resulted in tyrosine phosphorylation of bothStats5a and 5b, but nuclear translocation of only Stat5b (62).PRLhas been shown to activate Src in a variety of cell types, includingrat liver (63). Results from some recent studies indicate that proto-oncogene c-Myc potentiates Stat5a-driven gene expression, possibly functioning as a Stat5a coactivator in human breast cancer (54,64). Furthermore, PRL stimulates ubiquitination, internalization, and degradation of its receptors via catalytic activation of Jak2 (65), and it seems that Ser349 phosphorylation of PRLR is essential event in this complex Jak2-mediated signaling.
Ras-Raf-MAPK signaling pathway is a mechanism by which a variety of growth factors and cytokines mediate their proliferation action. Raf1 (mitogen activated protein kinase kinase kinase), MEK (mitogen activated protein kinase kinase), and MAP (mitogen activated protein kinase) are downstream kinases in this signaling pathway. Signaling through the SHC/GRB2/Ras/Raf/MEK/MAPK pathway (SHC-adaptor protein; GRB2-growth factor receptor-binding protein2; Ras-rat sarcoma) also directly stimulates proliferation and modulates Stat activity. PRL has been shownto activate this pathway in a number of PRL-dependent models(66), and mammary tumor cell lines (67-69), as wellas normal mouse mammary epithelial cells (68,69). PRL can also synergistically activate this pathwayvia cross-talk with other growth factors, depending on the phenotypeof the tumor cell. PRL-induced activation of Jak2 resulted intyrosine phosphorylation of erbB2, thereby increasing associationwith Grb2, and activating the Ras-MAPK pathway (70) including phosphorylation of some transcriptionfactors and thus increasing synthesis of the products of the fos gene family. Cross-talk betweenthe Stat and MAPK pathways at other points has been well documentedfor many cytokines, including PRL (71). MAPKs are able to phosphorylateStats on serine and threonine residues, which augments the activitiesof Stats1 and 3 (72).
PI3K (phosphoinositide 3 kinase) pathways
The complex between the Tec tyrosine kinase and the Vav family of guanine nucleotide exchange factors also inducibly associates with ligand-bound PRLR. This leads to the exchange of GDP for GTP on the small G protein Ras, resulting in its activation and stimulation of cellular motility. Activation of tyrosine kinases Tec and Akt (PKB-protein kinase B) is directly linked to the PRL-induced activation of PI3K. The phosphatase SHP-2 also binds to PRLR and potentiates its activity. Activation of PI3K generates phosphoinositides that serve as second messengers and canregulate multiple pathways important in oncogenesis, includingproliferation and cytoskeletal rearrangements, as well as inhibitionof apoptosis and angiogenesis (73-75). Activation of phosphoinositide cycle results in the stimulation of PKC (protein kinase C) pathway. PI3K could potentially be activated by PRL throughmultiple additional pathways. It can be a target of Ras (76),and the p85 regulatory subunit has been shown to associate withseveral downstream effectors and adaptors of cytokine and growthfactor receptors, including Stat5, Stat3, IRS1 (insulin receptor substrate 1), Gab1 (GRB2-associated binding protein 1) and Gab2 (GRB2-associated binding protein 2), and SHP-2 (Src homology-2 domain-containing protein-tyrosine phosphatase) (77,78). PI3K-generated phosphoinositides provide docking sites for Akt, as well as its upstream kinases. Phosphoinositide metabolites may also bind to guanine nucleotide exchangefactors, including Vav, as well as to Tec, a member of a largerfamily of tyrosine kinases. A constitutive complex of Tec and Vav (79) associates withPRLR in ligand-stimulated T47D (80).
Intranuclear action of PRL
Some literature data have indicated a functional role forPRL within the nucleus (81,82). These data stand in contrastwith the classic theory that postulates that peptide hormone actionis mediated only by cell surface receptors.Recent data, however, have revealed arole for the peptidyl prolyl isomerase cyclophilin B (CypB)in the nuclear transport and function of PRL (82). A complex between PRL and CypB is found in human serum, binds to the PRLR, and is endocytosed duringreceptor internalization. The PRL/CypB complexacts within the nucleus as a transcriptional inducer by facilitating the interactionof Stat5 with DNA by inducing the release of a repressor ofStat5, namely PIAS3 (83).
Rodent models of PRL action
Prolactin’s role in rodent mammary cancer has been well documented (1,84). There is a direct correlation between drug-induced hyperprolactinemia and increased tumor growth, and hypoprolactinemia and retarded tumor growth (1,85). PRL exposure enhances the development of chemicallyinduced mammary cancers in rodents (1,86,87). Overexpression of PRL in transgenic mice with increased activationof the PRLR is sufficient to induce the formation of mammarycancers at 11–15 months of age (88,89). Exposure to estrogen with secondary increases in circulatingPRL levels is able to restore susceptibility to chemical carcinogensin parous mice (90). In summary, numerous studies point toa role for PRL in increasing receptiveness to chemical carcinogensin rodent mammary glands.
Human breast cancer and PRL – in vivo investigations
Epidemiology of PRL and human breast cancer
Several epidemiological studies have indicated that PRL mayalso function as a progression factor for human breast cancer(8,91-93). A number of studies have evaluated the association between PRLlevels and several well-confirmed breast cancer risk factorssuch as parity and age at first birth, age at menarche and menopause, family history of breast cancer, mammographic density, ethnic differences, dietary intake, medication use, and prolactinomas.
PRL levels appear to decrease,at least modestly, with each additional pregnancy (94,95). Also, noindependent association between age at first birth and PRL levelwas observed (94). Overall, no significant associations between PRL and eitherage at menarche or age at menopause were reported (94,96). In a subset of subjects at risk with family history of breast cancer, basal serum PRL levels were significantly elevated (11).However, several other studies (94-96) offered scanty data to support association of the family history of breastcancer with PRL concentration.
Increased PRL levels were observedin postmenopausal women with increased breast tissue density (94,97), suggesting a measurable influence of PRL on breast epithelial and/or stromalproliferation.
Several studies evaluated PRL levels and dietaryintake (95,98) but consistent findings areyet to be reported.
A number of medications are known to increase (e.g., oral contraceptives,reserpine, haldol, cimetidine, and the phenothiazines) or decrease(e.g., levodopa) plasma PRL levels. Long-term use oforal contraceptives increases the risk of breast cancer (99). Cimetidine also increases PRL levels, but a fewstudies published have not shown any meaningful link with breast cancer (100). Women with prolactinomas have greatly elevated PRL levels.However, only a few case reports of breast cancer in women ormen with prolactinomas (101,102) and a small cohortstudy of 67 women with prolactinomas (103) have been publishedto date. Data of one recent study suggest modestpositive association between prolactin and breast cancer riskamong predominately premenopausal women; however, further follow-upis needed to increase statistical test power for subgroup analyses (104).
Genetic variations in PRL and PRL receptor (PRLR) genes as predictors of plasma PRL levels and breast cancer risk among African-American, native Hawaiian, Japanese-American, Latin, and white women were evaluated recently in a large multiethnic cohort study (105). In this comprehensive analysis covering 59 kb of the PRL locus and 210 kb of the PRLR locus, no significant association was found between common variation in these candidate genes and breast cancer risk or plasma PRL levels. The LD (linkage disequilibrium) characterization of PRL and PRLR in this multiethnic population provides a framework for studying these genes in relation to other disease outcomes that have been associated with PRL, as well as for larger studies of plasma PRL levels.
Clinical data about the association of PRL with breast cancer
The function of PRL in the etiology and progression of human breast cancer is not yet clear, and literature data are not consistent but, are even contradictory. However, there is significant evidence that PRL may play a role in human breast cancer.
The incidence of hyperprolactinemia was significantly higher in patients with metastatic breast cancer than in patients with non-metastatic breast cancer, or with mastopathy, or with advanced solid tumors of different histology (106). Hyperprolactinemia was almost exclusively found in patients with metastatic breast cancer during the course of the disease (8,107). Hyperprolactinemia was found to be an important indicator of unfavorable prognosis in node-positive breast cancer patients (108). Results of another study indicated the possible association of hyperprolactinemia and overexpression of p53 with aggressiveness of the tumor, early disease relapse or metastases, and poor overall survival in node-negative breast cancer patients (9). In primary tumors of stage II and stage III breast cancer patients, there was a significant increase in the frequency of PRL-positive tumors upon increase in the number of involved lymph nodes (109). With increasing tumor size, a significantly increased incidence of hyperprolactinemia was observed, hyperprolactinemic patients had a significantly increased risk of developing recurrent/metastatic disease, and seventy-eight per cent of their tumors showed positive immunoreactivity with PRL antibody indicating that breast tumors produce PRL which may act as a major local growth promoter (110). Results of some other studies are in agreement with those mentioned above. Circulating levels of PRL might be very useful diagnostic and prognostic marker in breast cancer patients (111), and a valuable parameter to assess treatment efficacy in breast carcinoma patients (112). Hyperprolactinemia is an indicator of disease progression and poor prognosis in metastatic breast cancer patients (113,114). Serum levels of PRL probably directly depend on the size of primary tumor in breast cancer patients, especially in those with hyperprolactinemia, but this is not a differentiation-dependent phenomenon (115).
In contrast, a surgery-induced rise in circulating PRL was associated with prolonged disease-free survival in operable breast carcinoma patients with or without axillary metastases (92,116).
Constitutive oncogenic signaling downstream of ErbB2 and Ras stabilizes PRLR via inhibitory phosphorylation of glycogen synthase kinase 3 beta (GSK3 beta) on Ser9. Importantly, inactivation of GSK3 beta correlates with elevated levels of PRLR protein in clinical human breast cancer specimens (39).
Increased prolactin levels are often associated with decreased sexual hormone levels. Association of hyperprolactinemia with reproductive disorders, amenorrhea and irregular menstrual cycles has already been known. Hyperprolactinemia in premenopausal women causes hypogonadism manifested by infertility, oligomenorrhea or amenorrhea and less often by galactorrhea (117). Patients with menstrual disturbances had higher PRL levels than women with normal menstrual function (118). However, results of one recent study have shown that no hormonal changes in serum levels of sexual hormones were found in women with hyperprolactinemia and sexual dysfunction (119). Furthermore, there are many contradictions concerning the association of female sexual steroids with cancer. Re-evaluation of earlier results supporting the carcinogenic capacity of estrogen has exhibited many shortcomings and controversies. Recently, clinical studies on hormone replacement therapy in postmenopausal women have justified beneficial anticancer effects in several organs, even in the female breast. The newly revealed association between estrogen deficiency and oral cancer risk also means a contradiction with regard to the traditional concept of estrogen-induced cancer. However cancers of highly estrogen dependent organs such as breast, endometrium and ovary exhibit both premenopausal and postmenopausal occurrence. In spite of different epidemiological data of these two groups of cancers, the mechanism of gene regulation disorder in the background of tumor initiation cannot act through entirely opposite pathways (120). This suggests that serious estrogen deficiency in moderately estrogen sensitive organs, and even mild estrogen deficiency in highly estrogen dependent organs is enough to provoke gene regulation disorders. New findings both on smoking- and hormone related cancers might lead to the same reversal; estrogen deficiency rather than estrogen itself may provoke cancer initiation (120).
Inhibition of PRL action
A decrease in PRLR levels achieved by either pharmacologic or genetic means in human breast cancer cells dramatically reduced transformation and tumorigenic properties of these cells (121). Tamoxifen (TAM), the first line of therapy in pre- and postmenopausal ER (estrogen receptor)-positive breast cancer patients also has an anti-prolactin action (122). Antilactogenic activity of TAM results from its interaction with the antilactogen binding site (ALBS) (123) which is located on the PRL receptor. ALBS is a member of the family of high affinity membrane-associated binding sites called antiestrogen binding sites (AEBS) (124). Antiestrogens, acting through the ALBS, inhibit the growth of PRL-responsive cells even in the absence of ER (125, 126). The results of these studies indicate that ALBS is in the PRL receptor, and that TAM and other related anti-estrogens may inhibit the growth of ER-negative human breast cancer cells in vitro through this mechanism (34). These data also suggest that TAM and other related drugs that act at the level of target tissue may be clinically useful in the treatment of hyperprolactinemic breast cancer patients. However, raloxifene, a selective estrogen receptor modulator and thus a breast cancer prevention agent, had no significant effect on PRL levels in premenopausal women at high risk for developing breast cancer (127).
PRL is synthesized by human breast cancer cells in culture, and acts in an autocrine/paracrine stimulatory loop within breast tissue. Both normal and malignant mammary cells contain both long and short forms of PRLR. PRL stimulates the cytoskeletal re-organization and motility of breast cancer cells. PRL may also influence mammary carcinogenesis bymodulating vascularization. Prolactin’s role in rodent mammary cancer has been well documented. Several epidemiological studies have indicated that PRL mayalso function as a progression factor for human breast cancer. Hyperprolactinemia was almost exclusively found in patients with metastatic breast cancer during the course of the disease, and it was found to be an important indicator of unfavorable prognosis in node-positive breast cancer patients. Taking into account all these data it could be concluded that both endocrine and autocrine PRL are involved in human breast carcinogenesis. However, much more work is needed to understand the signalingpathways used by PRL to promote tumorigenesis in mammary cells, andinteractions of these signaling cascades and their complex regulatoryloops with different oncogenes, growth factors and hormonesimportant in mammary carcinogenesis. Furthermore, the ongoing development of PRLR-specific antagonists may yield novel therapeutic strategies in treatment of human breast cancer based on blocking PRL actions at the endocrine and autocrine/paracrinelevels.
1. Welsch C, Nagasawa H. Prolactin and murine mammary tumorigenesis: a review. Cancer Res 1977;37:951-63.
2. Mershon J, Sall W, Mitchner N, Ben-Jonathan N. Prolactin is a local growth factor in rat mammary tumors. Endocrinology 1995;136: 3619-23.
3. Imagawa W, Tomooka Y, Hamamoto S, Nandi S. Stimulation of mammary epithelial cell growth in vitro: interaction of epidermal growth factor and mammogenic hormones. Endocrinology 1995;116:1514-24.
4. Vonderhaar BK. Prolactin: transport, function, ad receptors in mammary gland development and differentiation. In: Neville MC, Daniel CW, eds. The mammary gland. New York (NY): Plenum Publishing Corporation; 1987;383-483.
5. Das R, Vonderhaar BK. Prolactin as a mitogen in mammary cells. J Mammary Gland Biol Neoplasia 1997;2:29-39.
6. Vonderhaar BK. Prolactin: the forgotten hormone of human breast cancer. Pharmacol Ther 1998;79:169-78.
7. Bonneterre J, Peyrat JP, Beuscart R, Demaille A. Biological and clinical aspects of prolactin receptors in human breast cancer. J Steroid Biochem Mol Biol 1990;37:977-81.
8. Holtkamp W, Nagel GA, Wander HE, Rauschecker HF, von Heyden D. Hyperprolactinemia is a indicator of progressive disease and poor prognosis in advanced breast cancer. Int J Cancer 1984;34:323-8.
9. Patel DD, Bhatavdekar JM, Chikhlikar PR, Ghosh N, Suthar TP, Shah NG, et al. Node negative breast carcinoma: hyperprolactinemia and/or overexpression of p53 as an independent predictor of poor prognosis compared to newer and established prognosticators. J Surg Oncol 1996;62:83-92.
10. Bhatavdekar JM, Patel DD, Shah NG, Vora HH, Suthar TP, Ghosh N, et al. Prolactin as a local growth promoter in patients with breast cancer: GCRI experience. Eur J Surg Oncol 2000;26:540-7.
11. Love RR, Rose DR, Surawicz TS, Newcomb PA. Prolactin and growth hormone levels in premenopausal women with breast cancer and healthy women with a strong family history of breast cancer. Cancer 1991;68:1401-5.
12. Lachelin GCL, Yen SSC, Alksne JFN. Hormonal changes following hypophysectomy in humans. Obstet Gynecol 1977;50:333-9.
13. Manni A, Pearson OH, Brodkey J, Marshall JS. Transsphenoidal hypophysectomy in breast cancer: evidence for an individual role of pituitary and gonadal hormones in supporting tumor growth. Cancer 1979;44:2330-7.
14. Nolin JM, Witorsch RJ. Detection of endogenous immunoreactive prolactin in rat mammary epithelial cells during lactation. Endocrinology 1976;99:949-58.
15. Anderson E, Ferguson JE, Morten H, Shalet SM, Robinson EL, Howell A. Serum immunoreactive and bioactive lactogenic hormones in advanced breast cancer patients treated with bromocriptine and octreotide. Eur J Cancer 1993;29A:209-17.
16. Fields K, Kulig E, Lloyd RV. Detection of prolactin messenger RNA in mammary and other normal and neoplastic tissues by polymerase chain reaction. Lab Invest 1993;68:354-60.
17. Ginsburg E, Vonderhaar BK. Prolactin synthesis and secretion by human breast cancer cells. Cancer Res 1995;55:2591-5.
18. Clevenger CV, Chang W-P, Ngo W, Pasha TLM, Montone KT, Tomaszewski JE. Expression of prolactin and prolactin receptor in human breast carcinoma: evidence for an autocrine/paracrine loop. Am J Pathol 1995;146:695-705.
19. Kurtz A, Bristol LA, Toth BE, Lazar-Wesley E, Takacs L, Kacsoh B. Mammary epithelial cells of lactating rats express prolactin messenger ribonucleic acid. Biol Reprod 1993;48:1095-103.
20. Steinmetz RW, Grant AL, Malven PV. Transcription of prolactin gene in milk secretory cells of the rat mammary gland. J Endocrinol 1993;136:271-6.
21. Sinha YN. Structural variants of prolactin: occurrence and physiological significance. Endocr Rev 1995;16:354-69.
22. Clevenger CV, Russell DH, Appasamy PM, Prystowsky MB. Regulation of IL-2-driven T-lymphocyte proliferation by prolactin. Proc Natl Acad Sci USA 1990;87:6460-4.
23. Gellerson R, Kempf R, Teglmann R, DiMattia GE. Nonpituitary human prolactin gene transcription is indenpendent of pit-1 and differentially controlled in lymphocytes and in endometrial stroma. Mol Endocrinol 1994;8:356-73.
24. Richards RG, Hartman SM. Human dermal fibroblast cells express prolactin in vitro. J Invest Dermatol 1996;106:1250-5.
25. Ginsburg E, Das R, Vonderhaar BK. Prolactin: an autocrine growth factor in the mammary gland. In: Wilde CJ, Peaker M, Taylor E, eds. Biological Signalling in the Mammary Gland. Ayr, Scotland: Hannah Research Institute; 1997;47-58.
26. Reynolds C, Montone KT, Powell CM, Tomaszewski JE, Clevenger CV. Distribution of prolactin and its receptor in human breast carcinoma. Endocrinology 1997;138:5555-60.
27. Touraine P, Martini JF, Zafrani B, Durand JC, Labaille F, Malet C, et al. Increased expression of prolactin receptor gene assessed by quantitative polymerase chain reaction in human breast tumors versus normal breast tissue. J Clin Endocrinol Metab 1998;83:667-74.
28. Bazan JF. Structural design and molecular evolution of a cytokine receptor superfamily. Proc Natl Acad Sci USA 1990;87:6934-8.
29. Kelly PA, Djiane J, Postel-Vinay MC, Edery M. The prolactin/growth hormone receptor family. Endocr Rev 1991;12:235-51.
30. Kelly PA, Ali S, Rozakis M, Goujon L, Nagano M, Pellergini I, et al. The growth hormone/prolactin receptor family. Recent Prog Horm Res 1993;48:123-64.
31. Kline JB, Clevenger CV. Identification and characterization of the prolactin-binding protein (PRLBP) in human serum and milk. J Biol Chem 2001;276:24760-6.
32. Clevenger CV, Furth PA, Hankinson SE, Schuler LA. The role of prolactin in mammary carcinoma. Endocr Rev 2003;24:1-27.
33. Das R, Vonderhaar BK. Transduction of prolactin’s growth signal through both the long and short forms of the prolactin receptor. Mol Endocrinol 1995;9:1750-9.
34. Vanderhaar BK. Prolactin involvement in breast cancer. Endocrine-Related Cancer 1999;6:389-404.
35. Gill S, Peston D, Vonderhaar BK, Shousha S. Expression of prolactin receptors in normal, benign, and malignant breast tissue: an immunohistological study. J Clin Pathol 2001;54:956-60.
36. Ali S, Edery M, Pellegrini I, Lesueur L, Paly J, Djiane J, Kelly PA. The Nb2 form of prolactin receptor is able to activate a milk protein gene promoter. Mol Endocrinol 1992;6:1242-8.
37. Mertani HC, Garcia-Caballero T, Lambert A, Gerard F, Palayer C, Boutin JM, et al. Cellular expression of growth hormone and prolactin receptors in human breast disorders. Int J Cancer 1998;79:201-11.
38. Ormandy CJ, Hall RE, Manning DL, Robertson JFR, Blamey RW, Kelly PA, et al. Coexpression and cross-regulation of the prolactin receptor and sex steroid hormone receptors in breast cancer. J Clin Endocrinol Metab 1997;82:3692-9.
39. Plotnikov A, Li Y, Tran TH, Tang W, Palazzo JP, Rui H, Fuchs SY. Oncogene-mediated inhibition of glycogen synthase kinase 3 beta impairs degradation of prolactin receptor. Cancer Res 2008;68:1354-61.
40. Maus MV, Reilly SC, Clevenger CV. Prolactin as a chemoattractant for human breast carcinoma. Endocrinology 1999;140:5447-50.
41. Miller SL, Antico G, Raghunath PN, Tomaszewski JE, Clevenger CV. Nek3 kinase regulates prolactin-mediated cytoskeletal reorganization and motility of breast cancer cells. Oncogene 2007;26:4668-78.
42. Struman I, Bentzien F, Lee H, Mainfroid V, D’Angelo G, Goffin V, et al. Opposing actions of intact and N-terminal fragments of the human prolactin/growth hormone family members on angiogenesis: an efficient mechanism for the regulation of angiogenesis. Proc Natl Acad Sci USA 1999;96:1246-51.
43. Ferrara N, Clapp C, Weiner R. The 16K fragment of prolactin specifically inhibits basal or fibroblast growth factor stimulated growth of capillary endothelial cells. Endocrinology 1991;129:896-900.
44. Clapp C, Martial JA, Guzman RC, Rentier-Delrue F, Weiner RI. The 16-kilodalton N-terminal fragment of human prolactin is a potent inhibitor of angiogenesis. Endocrinology 1993;133:1292-9.
45. D’Angelo G, Martini JF, Iiri T, Fantl WJ, Martial J, Weiner RI. 16K human prolactin inhibits vascular endothelial growth factor-induced activation of Ras in capillary endothelial cells. Mol Endocrinol 1999;13: 692-704.
46. Lee H, Struman I, Clapp C, Martial J, Weiner RI. Inhibition of urokinase activity by the antiangiogenic factor 16K prolactin: activation of plasminogen activator inhibitor 1 expression. Endocrinology 1998;139:3696-703.
47. Clapp C, Weiner R. A specific, high affinity, saturable binding site for the 160 kilodalton fragment of prolactin on capillary endothelial cells. Endocrinology 1992;130:1380-6.
48. Goldhar AS, Vonderhaar BK, Trott JF, Hovey RC. Prolactin-induced expression of vascular endothelial growth factor via Erg-1. Mol Cell Endocrinol 2005;232:9-19.
49. Clapp C, Thebault S, de la Escalera GM. Role of prolactin and vasoinhibins in the regulation of vascular function in mammary gland. J Mammary Gland Biol Neoplasia 2008;13:55-67.
50. Rane SG, Reddy EP. Janus kinases: components of multiple signaling pathways. Oncogene 2000;19:5662-79.
51. Clevenger CV, Kline JB. Prolactin receptor signal transduction. Lupus 2001;10:706-18.
52. Yu-Lee LY, Luo GY, Book ML, Morris SM. Lactogenic hormone signal transduction. Biol Reprod 1998;58:295-301.
53. Bole-Feysot C, Goffin V, Edery M, Binart N, Kelly PA. Prolactin (PRL) and its receptor: actions, signal transduction pathways and phenotypes observed in PRL receptor knockout mice. Endocr Rev 1998;19:225-68.
54. Fang F, Antico G, Zheng J, Clevenger CV. Quantification of PRL/STAT 5 signaling with a novel pGL4-CISH reporter. BMC Biotechnology 2008;8:11.
55. Darnell Jr JE, Kerr IM, Stark GR. Jak-STAT pathways and transcriptional activation in response to IFNs and other extracellular signaling proteins. Science 1994;264:1415-21.
56. DaSilva L, Rui H, Erwin RA, Howard OMZ, Kirken RA, Malabarba MG, et al. Prolactin recruits STAT1, STAT3, and STAT5 independent of conserved receptor tyrosine TYR402, TYR479, TYR515 and TYR 580. Mol Cell Endocrinol 1996;117:131-40.
57. Watson CJ, Miller WR. Elevated levels of members of the STAT family of transcription factors in breast carcinoma nuclear extracts. Br J Cancer 1995;71:840-4.
58. Bowman T, Garcia R, Turkson J, Jove R. STATs in oncogenesis. Oncogene 2000;19:2474-88.
59. Brockman JL, Schroeder MD, Schuler LA. Prolactin activates the cyclin D1 promoter via the JAK2-STAT pathway. Mol Endocrinol 2002;16:774-84.
60. Kazansky AV, Rosen JM. Signal transducers and activators of transcription 5B potentiate v-Src-mediated transformation of NIH-3T3 cells. Cell Growth Differ 2001;12:1-7.
61. Liu X, Robinson GW, Gouilleux F, Groner B, Henninghausen L. Cloning and expression of Stat5 and an additional homologue (Stat 5b) involved in prolactin signal transduction in mouse mammary tissue. Proc Natl Acad Sci USA 1995;92:8831-5.
62. Kazansky AV, Kabotyanski EB, Wsyzomierski SL, Mancini MA, Rosen JM Differential effects of prolactin and src/abl kinases on the nuclear translocation of STAT5B and STAT5A. J Biol Chem 1999;274:22484-92.
63. Berlanga JJ, Vara JAF, Martín-Pérez J, García-Ruiz JP. Prolactin receptor is associated with c-src kinase in rat liver. Mol Endocrinol 1995;9:1461-7.
64. Fang F, Rycyzyn MA, Clevenger CV. Role of c-Myb during prolactin-induced signal transducer and activator of transcription 5a signaling in breast cancer cells. Endocrinology 2009;150:1597-606.
65. Swaminathan G, Varghese B, Thangavel C, Carbone CJ, Plotnikov A, Kumar KG, et al. Prolactin stimulates ubiquitination, initial internalization, and degradation of its receptor via catalytic activation of Janus kinase 2. Endocrinology 2008;196:R1-7.
66. Clevenger CV, Torigoe T, Reed JC. Prolactin induces rapid phosphorylation and activation of prolactin receptor associated Raf-1 kinase in a T-cell line. J Biol Chem 1994;269:5559-65.
67. Llovera M, Pichard C, Bernichtein S, Jeay S, Touraine P, Kelly PA, Goffin V. Human prolactin (hPRL) antagonists inhibit hPRL-activated signaling pathways involved in breast cancer cell proliferation. Oncogene 2000;19:4695-705.
68. Das R, Vonderhaar BK. Activation of raf-1 MEK, and MAP kinase in prolactin responsive mammary cells. Breast Cancer Res Treat 1996;40:141-9.
69. Das R, Vonderhaar BK. Involvement of SHC, GRB2, SOS and RAS in prolactin signal transduction in mammary epithelial cells. Oncogene 1996;13:1139-45.
70. Yamauchi T, Yamauchi N, Ueki K, Sugiyama T, Waki H, Miki H, et al. Constitutive tyrosine phosphorylation of ErbB-2 via Jak2 by autocrine secretion of prolactin in human breast cancer. J Biol Chem 2000;275:33937-44.
71. Gao J, Horseman ND. Prolactin-independent modulation of the ß-casein response element by Erk2 MAP kinase. Cell Signal 1999;11:205-10.
72. Decker T, Kovarik P. Serine phosphorylation of STATs. Oncogene 2000;19:2628-37.
73. Roymans D, Slegers H. Phosphatidylinositol 3-kinases in tumor progression. Eur J Biochem 2001;268:487-98.
74. Blume-Jensen P, Hunter T. Oncogenic kinase signalling. Nature 2001; 11:355-65.
75. Cantrell DA. Phosphoinositide 3-kinase signalling pathways. J Cell Sci 2001;114:1439-45.
76. Rodriguez-Viciana P, Marte BM, Warne PH, Downward J. Phosphatidylinositol 3’ kinase: one of the effectors of Ras. Philos Trans R Soc Lond B Biol Sci 1996;351:225-31.
77. Constantino S, Santos R, Lacronique V, Bouchaert I, Monni R, Bernard O, et al. Constitutively active STAT5 variants induce growth and survival of hematopoietic cells through a PI 3-kinase/Akt dependent pathway. Oncogene 2001;20:2080-90.
78. Craddock BL, Hobbs J, Edmead CE, Welham MJ. Phosphoinositide 3-kinase-dependent regulation of interleukin-3-induced proliferation: involvement of mitogen-activated protein kinases, SHP2 and Gab2. J Biol Chem 2001;276:24274-83.
79. Kline JB, Moore DJ, Clevenger CV. Activation and association of the Tec tyrosine kinase with the human prolactin receptor: mapping of a Tec/Vav1-receptor binding site. Mol Endocrinol 2001;15:832-41.
80. Clevenger CV, Ngo W, Luger SM, Gewirtz AM. Vav is necessary for prolactin-stimulated proliferation and is translocated into the nucleus of a T-cell line. J Biol Chem 1995;270:13246-53.
81. Clevenger CV, Altmann SW, Prystowsky MB. Requirement of nuclear prolactin for interleukin-2-stimulated proliferation of T lymphocytes. Science 1991;253:77-9.
82. Rycyzyn MA, Reilly SC, O’Malley K, Clevenger CV. Role of cyclophilin B in PRL signal transduction and nuclear retrotranslocation. Mol Endocrinol 2000;14:1175-86.
83. Rycyzyn MA, Clevenger CV. The intranuclear prolactin/cyclophilin B complex as a transcriptional inducer. Proc Natl Acad Sci USA 2002;99:6790-5.
84. Vonderhaar BK, Biswas R. Prolactin effects and regulation of its receptors in human mammary tumor cells. In: Medina D, Kidwell W, Hepner G, Anderson E, eds. Cellular and Molecular Biology of Mammary Cancer. New York: Plenum Publishing Corp; 1987;205-19.
85. Welsch CW, Gribler C. Prophylaxis of spontaneously developing mammary carcinoma in C3H/HeJ female mice by suppression of prolactin. Cancer Res 1973;33:2939-46.
86. Welsch CW. Prolactin and the development and progression of early neoplastic mammary gland lesions. Cancer Res 1978;38:4054-8.
87. Welsch CW, Goodrich-Smith M, Brown CK, Roth L. The prophylaxis of rat and mouse mammary gland tumorigenesis by suppression of prolactin secretion: a reappraisal. Breast Cancer Res Treat 1981;1:225-32.
88. Wennbo H, Gebre-Medhin M, Griti-Linde A, Ohlsson C, Isaksson OGP, Tornell J. Activation of the prolactin receptor but not the growth hormone receptor is important for induction of mammary tumors in transgenic mice. J Clin Invest 1997;100:2744-51.
89. Wennbo H, Tornell J. The role of prolactin and growth hormone in breast cancer. Oncogene 2000;19:1072-6.
90. Thordarson G, Van Horn K, Guzman RC, Nandi S, Talamantes F. Parous rats regain high susceptibility to chemically induced mammary cancer after treatment with various mammotropic hormones. Carcinogenesis 2001;22:1027-33.
91. Wang DY, Stepniewska KA, Allen DS, Fentiman IS, Bulbrook RD, Kwa HG, et al. Serum prolactin levels and their relationship to survival in women with operable breast cancer. J Clin Epidemiol 1995;48:959-68.
92. Lissoni P, Barni S, Cazzaniga M, Ardizzoia A, Rovelli F, Tancini G, et al. Prediction of recurrence in operable breast cancer by postoperative changes in prolactin secretion. Oncology 1995;52:439-42.
93. Bhatavdekar JM, Shah NG, Balar DB, Patel DD, Bhaduri A, Trivedi SN, et al. Plasma prolactin as an indicator of disease progression in advanced breast cancer. Cancer 1990;65:2028-32.
94. Wang DY, De Stavola BL, Bulbrook RD, Allen DS, Kwa HG, Verstraeten AA, et al. The permanent effect of reproductive events on blood prolactin levels and its relation to breast cancer risk: a population study of postmenopausal women. Eur J Cancer Clin Oncol 1988;24:1225-31.
95. Ingram DM, Nottage EM, Roberts AN. Prolactin and breast cancer risk. Med J Aust 1990;153:469-73.
96. Hankinson SE, Colditz GA, Hunter DJ, Manson JE, Willett WC, Stampfer MJ, et al. Reproductive factors and family history of breast cancer in relation to plasma estrogen and prolactin levels in postmenopausal women in the Nurses’ Health Study (United States). Cancer Causes Control 1995;6:217-24.
97. Boyd NF, Stone J, Martin L, Minkin S, Yaffe M. Mammographic densities and the growth hormone-IGF-1 prolactin axis. Sunnybrook and Women’s College Hospital, Proc 92nd Meeting of the American Association for Cancer Research, New Orleans, LA, 2001;558.
98. Martini MC, Dancisak BB, Haggans CJ, Thomas W, Slavin JL. Effects of soy intake on sex hormone metabolism in premenopausal women. Nutr Cancer 1999;34:133-9.
99. Collaborative Group on Hormonal Factors in Breast Cancer. Breast cancer and hormonal contraceptives: collaborative reanalysis of individual data on 53,297 women with breast cancer and 100,239 women without breast cancer from 54 epidemiological studies. Lancet 1996;347:3106-8.
100. Rossing MA, Scholes D, Cushing-Haugen KL, Voigt LF. Cimetidine use and risk of prostate and breast cancer. Cancer Epidemiol Biomarkers Prev 2000;9:319-23.
101. Strungs I, Gray RA, Rigby HB, Strutton G. Two case reports of breast carcinoma associated with prolactinoma. Pathology 1997;29:320-3.
102. Volm MD, Talamonti MS, Thangavelu M, Gradishar WK. Pituitary adenoma and bilateral male breast cancer: an unusual association. J Surg Oncol 1997;64:74-8.
103. Popovic V, Damjanovic S, Micic D, Nesovic M, Djurovic M, Petakov M, et al. Increased incidence of neoplasia in patients with pituitary adenomas. The Pituitary Study Group. Clin Endocrinol (Oxf) 1998;49:441-5.
104. Tworoger SS, Sluss P, Hankinson SE. Association between plasma prolactin concentrations and risk of breast cancer among predominately premenopausal women. Cancer Res 2006;66:2476-82.
105. Lee SA, Haiman CA, Burtt NP, Pooler LC, Cheng I, Kolonel LN, Pike MC, Altshuler D, Hirschhorn JN, Henderson BE, Stram DO. A comprehensive analysis of common genetic variations in prolactin (PRL) and PRL receptor (PRLR) genes in relation to plasma prolactin levels and breast cancer risk: the multiethnic cohort. BMC Med Genet 2007;8:72.
106. Holtkamp W, von Heyden D, Rauschecker H, Nagel GA. Plasma-prolactin concentrations in breast cancer at various stages, in mastopathy and other malignant tumors. Schweiz Med Wochenschr 1983;113:1513-20.
107. Holtkamp W, Wuttke W, Nagel GA, Michel U, Rauschecker H. Pathophysiology of hyperprolactinemia in breast cancer. Onkologie 1988;11:86-103.
108. Bhatavdekar JM, Patel DD, Vora HH, Ghosh N, Shah NG, Karelia NH, et al. Node-positive breast cancer: prognostic significance of the plasma prolactin compared with steroid receptors and clinicopathological features. Oncology Reports 1994;1:841-5.
109. Bhatavdekar JM, Patel DD, Shah NG, Vora HH, Suthar TP, Chikhlikar PR, et al. Prognostic significance of immunohistochemically localized biomarkers in stage II and stage III breast cancer: a multivariate analysis. Ann Surg Oncol 2000;7:305-11.
110. Bhatavdekar JM, Patel DD, Shah NG, Vora HH, Suthar TP, Ghosh N, et al. Prolactin as a local growth promoter in patients with breast cancer: GCRI experience. Eur J Surg Oncol 2000;26:540-7.
111. Mujagić Z, Mujagić H. Diagnostic and prognostic usefulness of prolactin (PRL) in breast cancer (BC). Proceedings of ASCO, San Francisco 2001;20:43b.
112. Mujagić Z, Mujagić H. Circulating levels of prolactin as an indicator of effectiveness of therapy in breast cancer patients. Int J Cancer 2002; Suppl 13:216.
113. Mujagić Z, Mujagić H. Prognostic significance of circulating levels of prolactin (PRL) in metastatic breast cancer (MBC). Proceedings of ASCO, Chicago 2003;22:49.
114. Mujagić Z, Mujagić H. Importance of serum prolactin determination in metastatic breast cancer patients. Croat Med J 2004;45:176-80.
115. Mujagić Z, Mujagić H. The relationship of circulating prolactin levels to the size of primary tumor in breast cancer patients. Turk J Bioch 2004;29:277-81.
116. Mandala M, Lissoni P, Ferretti G, Rocca A, Torri V, Moro C, et al. Postoperative hyperprolactinemia could predict longer disease-free and overall survival in node-negative breast cancer patients. Oncology 2002;63:370.
117. Gomez F, Reyes FI, Faiman C. Nonpuerperal galactorrhea and hyperprolactinemia. Clinical findings, endocrine features and therapeutic responses in 56 cases. Am J Med 1977;62:648-60.
118. Berinder K, Stackenäs I, Akre O, Hirschberg AL, Hulting AL. Hyperprolactinemia in 271 women: up to three decade of clinical follow-up. Clin Endocrinol (Oxf) 2005;63:450-5.
119. Kadioglu P, Yalin AS, Tiryakioglu O, Gazioglu N, Oral G, Sanli O, Onem K, Kadioglu A. Sexual dysfunction in women with hyperprolactinemia: a pilot study report. J Urol. 2006;176:841-2.
120. Suba Z. Carcinogenesis theory based on estrogen deficiency. Orv Hetil 2009;150:1155-6.
121. Plotnikov A, Varghese B, Tran TH, Liu C, Rui H, Fuchs SY. Impaired turnover of prolactin receptor contributes to transformation of human breast cells. Cancer Res 2009;69:OF1-8.
122. Vonderhaar BK, Banerjee R. Is tamoxifene also an antilactogen? Mol Cell Endocrinol 1991;79:C159-C163.
123. Das R, Biswas R, Vonderhaar BK. Characteristics of the antilactogen binding site in mammary gland membranes. Mol Cell Endocrinol 1993;98:1-8.
124. Sutherland RL, Murphy LC, Foo MS, Green MD, Whybourne AM, Krozowski ZS. High-affinity anti-oestrogen binding sites distinct from the oestrogen receptor. Nature 1980;288:273-5.
125. Das R, Vonderhaar BK. Prolactin as a mitogen in mammary cells. J Mammary Gland Biol Neoplasia 1997;2:29-39.
126. Das R, Vonderhaar BK. Tamoxifen inhibits prolactin signal transduction in estrogen receptor negative NOG-8 mammary epihelial cells. Cancer Letters 1997;116:41-6.
127. Faupel-Badger JM, Prindiville SA, Venzon D, Vonderhaar BK, Zujewski JA, Eng-Wong J. Effects of raloxifene on circulating prolactin and estradiol levels in premenopausal women at high risk for developing breast cancer. Cancer Epidemiol Biomarkers Prev 2006;15:1153-8.